

Exploring the link between small airway disease and cardiovascular disease in patients with chronic obstructive pulmonary disease

Submission date 21/02/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 15/03/2023	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 04/03/2026	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

To date, no studies have been carried out to assess the relationship between cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) according to the presence of small airway disease (SAD). SAD is a condition of small airways leading to hyperinflation, barrel chest, increased symptoms and disease progression. The CLAIM study is the only well-designed study correlating cardiovascular events and hyperinflation providing an indirect indication for dual bronchodilator therapy in hyperinflated COPD patients. Briefly, dual bronchodilation therapy significantly improved cardiac function as measured by left-ventricular end-diastolic volume. Unfortunately, CLAIM being a randomized controlled trial does not provide information on the potential impact of comorbidities in these patients. Therefore, the main objective of this study (the ARCADIA study) is to assess the risk of CVD in COPD patients with SAD in a real-life setting. In these patients, the correlation between CVD, mortality, and acute exacerbations in COPD will be assessed.

Who can participate?

Patients aged ≥ 40 years old with a clinical and functional diagnosis of COPD and no acute exacerbation of COPD in the last 3 months

What does the study involve?

The ARCADIA Study is a one-year study of 500 COPD patients with SAD from 20 pulmonary centers in Italy. The study will occur between January 2023 and January 2024 and will involve 3 visits for each patient.

What are the possible benefits and risks of participating?

The patients participating in the ARCADIA study will be well-monitored from a respiratory and cardiovascular point of view and they will reach a greater knowledge concerning the real status of their disease and comorbidities. There aren't risks for the patients, because the ARCADIA study is an observational, non-pharmacological, non-interventional study in which the clinicians will administer a survey.

Where is the study run from?

Tor Vergata General Hospital Foundation (Fondazione Policlinico Tor Vergata), Rome (Italy)

When is the study starting and how long is it expected to run for?

September 2022 to January 2025

Who is funding the study?

1. Ministry of University and Research (MUR) National Recovery and Resilience Plan (PNRR) (M4C2I1.3 PE6 project PE00000019 Heal Italia) (Italy)
2. Società Italiana Pneumologia (SIP), Study Group COPD and Comorbidities (Italy)

Who is the main contact?

Fondazione Policlinico Tor Vergata, studioarcadia@med.uniroma2.it (Italy)

Contact information

Type(s)

Principal investigator

Contact name

Prof Paola Rogliani

ORCID ID

<https://orcid.org/0000-0001-7801-5040>

Contact details

Via Montpellier 1

Rome

Italy

00133

+39 06 2090 4656

paola.rogliani@uniroma2.it

Type(s)

Scientific

Contact name

Prof Luigino Calzetta

ORCID ID

<https://orcid.org/0000-0003-0456-069X>

Contact details

Via Gramsci, 14

Parma

Italy

43126

+39 06 7259 6666

luigino.calzetta@uniroma2.it

Type(s)

Scientific

Contact name

Prof Dejan Radovanovic

ORCID ID

<https://orcid.org/0000-0002-9013-3418>

Contact details

Via G.B Grassi, 74

Milano

Italy

20157

+39 02 39042321

dejan.radovanovic@asst-fbf-sacco.it

Type(s)

Scientific

Contact name

Dr Josuel Ora

ORCID ID

<https://orcid.org/0000-0001-9877-7851>

Contact details

Via Montpellier 1

Rome

Italy

00133

+39 06 2090 4656

josuel.ora@ptvonline.it

Type(s)

Public

Contact name

Dr Elena Pistocchini

Contact details

Via Montpellier 1

Rome

Italy

00133

+39 06 2090 4656

elena.pistocchini@uniroma2.it

Additional identifiers

Study information

Scientific Title

Assessing the relationship between cardiovascular and small airway disease and acute events in COPD: the ARCADIA study protocol

Acronym

ARCADIA

Study objectives

To the best of our knowledge, to date no studies have been carried out an assessment the relationship between cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) according to the presence of small airway disease (SAD). Therefore, the main objective of this study will be to assess the risk of CVD in COPD patients with SAD in a real-life setting. The correlation between CVD, mortality and acute exacerbation of COPD will be also evaluated in events in these patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 20/12/2022, Independent Ethics Committee (Comitato Etico Indipendente) (Tor Vergata General Hospital [Policlinico Tor Vergata], Viale Oxford 81, Rome, Italy; +39 0620900035; comitato.etico@ptvonline.it), ref: R.S 259.22

Study design

Prospective multicenter pilot observational cohort study

Primary study design

Observational

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Cardiovascular disease (CVD) and small airway disease (SAD) in patients with chronic obstructive pulmonary disease (COPD)

Interventions

The ARCADIA study is a prospective, multicenter, pilot, observational, cohort study that will be conducted in ≥ 20 pulmonary centers from all over Italy. The goal of this study is to enroll ≥ 500 patients. The study will consist of an observational period lasting up to 52 weeks, with the possibility of extending the observation up to 3 years for each patient. Between January 2023 and January 2024, patients will be enrolled on the study.

Patients will attend the centres during the routine outpatient visits scheduled for their pathology. COPD patients will be recruited according to the ARCADIA inclusion/exclusion criteria and according to their willingness to participate in this study. Enrolled patients will be provided written informed consent to participate in the study.

The study will be composed of 3 different visits, as follows: visit 1 (first patient evaluation at time 0, in person), visit 2 (second visit at time 6 ± 1 month from visit 1, phone call), visit 3 (third

visit at time 12±2 months from visit 1, phone call). Questionnaires used during visit 1 include the modified British Medical Research Council Questionnaire (mMRC) and the COPD Assessment Test (CAT). During the phone calls in visits 2 and 3, bespoke questionnaires will be used. Specifically, information regarding AECOPD, hospitalizations, SARS-CoV2 infections, and current pharmacological therapy will be collected.

The main endpoint will be to assess the risk of CVD in patients with COPD affected by SAD; the secondary endpoints will be to assess mortality, exacerbation risk and exacerbation characteristics in the same patients.

Intervention Type

Other

Primary outcome(s)

Cardiovascular disease risk in patients with COPD affected by small airway disease (SAD) measured using a bespoke questionnaire at visit 2 (after 6±1 months from visit 1) and visit 3 (after 12±2 months from visit 1)

Key secondary outcome(s)

Mortality, exacerbation risk and exacerbation characteristics in the same patients measured using a bespoke questionnaire at visit 2 (after 6±1 months from visit 1) and visit 3 (after 12±2 months from visit 1)

Completion date

31/01/2025

Eligibility

Key inclusion criteria

1. Clinical and functional diagnosis of COPD
2. Forced expiratory volume in the 1st second (FEV1)/forced vital capacity (FVC) ratio <0.7 and /or FEV1/FVC (or FEV1/vital capacity [VC]) < lower limit of normal (LLN)
3. Clinical stability ≥3 months (no mild moderate or severe exacerbations)
4. Both genders
5. Age ≥40 years
6. Smoking history ≥10 p/y

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

40 years

Upper age limit

100 years

Sex

All

Total final enrolment

575

Key exclusion criteria

1. Previous or current history of bronchial asthma
2. Restrictive lung disease or interstitial lung disease
3. Active or under treatment neoplasms
4. Shift of inhalation therapy in the 3 months prior to study entry
5. Inability to perform reliable and repeatable pulmonary function tests
6. Oxygen therapy >18 hours a day
7. Diagnosed with clinically significant bronchiectasis (overt diagnosis of bronchiectasis on chest computed tomography [CT] which is the patient's primary diagnosis)
8. Severe obstructive sleep apnea syndrome (apnea/hypopnea index >30/h)
9. Pregnancy

Date of first enrolment

31/01/2023

Date of final enrolment

31/01/2024

Locations

Countries of recruitment

Italy

Study participating centre

Fondazione Policlinico Tor Vergata

Viale Oxford, 81

Rome

Italy

00133

Study participating centre

Ospedale Luigi Sacco, Polo Universitario

Via Giovanni Battista Grassi, 74

Milano

Italy

20157

Study participating centre
Azienda Ospedaliera Universitaria di Siena
Viale Mario Bracci, 11
siena
Italy
53100

Study participating centre
Ospedale San Gerardo
Via G. B. Pergolesi, 33
Monza
Italy
20900

Study participating centre
Ospedale San Paolo
Via Antonio di Rudinì, 8
Milano
Italy
20142

Study participating centre
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Via Francesco Sforza, 35
Milano
Italy
20122

Study participating centre
Istituto clinico Humanitas
Via Alessandro Manzoni, 56
Rozzano
Italy
20089

Study participating centre
Azienda Ospedaliero-Universitaria di Parma
Viale Antonio Gramsci, 14
Parma
Italy
43126

Study participating centre

Azienda Ospedaliera Universitaria Policlinico G. Rodolio San Marco

Viale Carlo Azeglio Ciampi

Catania

Italy

95121

Study participating centre

Policlinico di Bari, Ospedale Giovanni XXIII

piazza Giulio Cesare n.11

Bari

Italy

70120

Study participating centre

Fondazione IRCCS Policlinico San Matteo

Viale Camillo Golgi, 19

Pavia

Italy

27100

Study participating centre

Azienda Ospedale-Università Padova

Via Giustiniani, 2

Padova

Italy

35128

Study participating centre

Azienda Ospedaliera Policlinico Paolo Giaccone

Via del Vespro, 129

Palermo

Italy

90127

Study participating centre

Ospedale Molinette, Città della Scienza e della Salute

Corso Bramante, 88

Torino
Italy
10126

Study participating centre

Arcispedale Sant'Anna

Via Aldo Moro, 8

Ferrara

Italy

44124

Study participating centre

IRCCS Ospedale Policlinico San Martino

Largo Rosanna Benzi, 10

Genova

Italy

16132

Study participating centre

ASST Ospedale Giovanni XXIII

Piazza OMS, 1

Bergamo

Italy

24127

Study participating centre

Azienda Ospedaliera Universitaria Integrata

Piazzale Aristide Stefani, 1

Verona

Italy

37126

Study participating centre

ASST Lodi, Ospedale di Codogno

Viale Guglielmo Marconi, 1

Codogno, Lodi

Italy

26845

Study participating centre**Università di Sassari**

Piazza Università, 21

Sassaro

Italy

07100

Study participating centre**Università di Foggia - Azienda Ospedaliero-Universitaria "Policlinico Riuniti"**

Viale Pinto Luigi, 1

Foggia

Italy

71122

Study participating centre**Sapienza, Università di Roma**

Piazzale Aldo Moro, 5

Roma

Italy

00185

Sponsor information**Organisation**

University of Rome Tor Vergata

ROR<https://ror.org/02p77k626>**Funder(s)****Funder type**

Government

Funder Name

Ministero dell'Università e della Ricerca

Alternative Name(s)

Ministry for Universities and Research, Italy, MUR Ministero dell'Università e della Ricerca, Ministry for Universities and Research, Ministero Università e Ricerca, Italian Ministero Università e Ricerca, MUR, M.U.R.

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Italy

Funder Name

Società Italiana di Pneumologia

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository. The electronic Case Report Forms (eCRF) will be stored in an Excel file format.

- The name of the repository: To be defined
- A persistent weblink and the process for requesting access (if non-publicly available): To be defined
- Timing for availability: 24 months
- Whether consent from participants was required and obtained: Yes
- Comments on data anonymization: First two letters of name plus first two letters of surname, plus year of birth plus centre code.
- Any ethical or legal restrictions: Not applicable
- Any additional comments: Not applicable

IPD sharing plan summary

Stored in non-publicly available repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		04/07/2023	07/07/2023	Yes	No
Protocol file			28/02/2023	No	No